AMAxel Maurice-Szamburski

Axel Maurice-Szamburski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Axel Maurice-Szamburski has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Romain Rozier

    Department of Anesthesiology and Intensive Care Medicine, CHU L’Archet University Hospital, Nice, France

    8 shared publications
  • Pascal Auquier

    Laboratoire de Santé Publique, 264 rue Saint Pierre, 13005, Marseille, France

    6 shared publications
  • Anderson Loundou

    Laboratoire de Santé Publique, 264 rue Saint Pierre, 13005, Marseille, France

    3 shared publications
  • Philippe Cuvillon

    CHU Nîmes Carémeau, Nîmes, France

    3 shared publications
  • Sophie Bringuier

    Department of Medical Statistics, and Epidemiology, Montpellier University Hospital, Montpellier, France; Debrest Institute of Epidemiology and Public Health IDESP, UMR INSERM, University of Montpellier, Montpellier, France; Department of Anaesthesiology and Critical Care Medicine, Lapeyronie University Hospital, and Montpellier NeuroSciences Institute, Inserm U 1051, Montpellier, France

    3 shared publications
  • Thierry Gazeau

    Clinique Jules Verne, Department of Anaesthesiology, Nantes, France

    3 shared publications

Latest Publications

  • Peak expectations: a question of power and timing

    by Romain Rozier, Alexandre Destere, Axel Maurice-Szamburski

  • Assessing ChatGPT and Gemini Responses to Common Patient Questions Regarding Augmentation Mammaplasty

    by Pharel Njessi, Axel Maurice-Szamburski, Chris Amro, Carter J. Boyd, Jérôme Laloze, Elise Lupon

    Large language models (LLMs) are becoming a common source of medical information for patients. This study aimed to evaluate and compare the quality and readability of ChatGPT and Google's Gemini in answering frequently asked questions (FAQs) about augmentation mammaplasty (AM). Ten AM FAQs were submitted to ChatGPT (GPT-4.1 mini) and Gemini (2.5 Flash). Responses were de-identified and independently rated by two board-certified plastic surgeons and one senior resident using the Global Quality Score (GQS). Readability was assessed using the Flesch Reading Ease (FRE) and Flesch-Kincaid Grade Level (FKGL). Paired comparisons used the Wilcoxon signed-rank test for per-question median GQS, inter-rater agreement used Kendall's W, and readability used paired tests as appropriate. Across 60 individual ratings (3 raters × 10 items × 2 models), per-question median GQS was 5 for 9/10 ChatGPT answers and 10/10 Gemini answers; the paired comparison showed no significant difference (Wilcoxon Z = -1.00; p = 0.317; effect size r = 0.32). Inter-rater agreement was W = 0.24 (ChatGPT, p = 0.091) and W = 0.60 (Gemini, p = 0.002). ChatGPT produced more readable outputs (FRE: 46.53 vs 43.70, p = 0.243; FKGL: 9.71 vs 11.43, p = 0.002), indicating approximately two US grade levels of easier reading. ChatGPT and Gemini both generated high-quality answers to common AM FAQs, with no difference in quality based on GQS. ChatGPT's responses were significantly easier to read according to FKGL. LLMs may support patient education when implemented with clinician oversight to mitigate limitations and prevent misinformation. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .


  • Open Access

    Comfort-Focused Assessment and Patient-Reported Experience After Regional versus General Anaesthesia: Post Hoc Analysis of a Cluster-Randomised Trial

    by Axel Maurice-Szamburski, Romain Rozier, Nicolas Fusco, Ludovic Meuret, Anderson Loundou, Pascal Auquier, Hélène Beloeil

  • Impact of epinephrine on ropivacaine pharmacokinetics in TAP blocks: a randomized controlled trial

    by Romain Rozier, Yann Le Guennec, Xavier Capdevila, Eric Le Louarn, Juliette Balbo, Thibaud Lavrut, Patrick Baque, Olivier Perus, Alexandre Destere, Axel Maurice-Szamburski

    Background Ropivacaine is commonly used in abdominal wall blocks due to its safety profile, and the addition of epinephrine is hypothesized to prolong analgesic duration and reduce systemic absorption. However, previous studies have been limited by non-weight-adjusted dosing and potential pharmacokinetic interactions, and inadequate investigation of the free form of ropivacaine. Objective To characterize and compare the pharmacokinetics of total and free ropivacaine administered at a weight-adjusted dose of 1 mg/kg in Transversus Abdominis Plane (TAP) blocks, with and without epinephrine (1:200 000; 5 µg/mL). Methods In this randomized controlled trial, 40 patients undergoing laparoscopic colectomy received bilateral TAP blocks with ropivacaine alone (TAP/E−) or ropivacaine with epinephrine (TAP/E+). Pharmacokinetic parameters, including maximum plasma concentration (Cmax), time to Cmax (Tmax), and area under the concentration-time curve, were assessed over 240 min. Secondary outcomes included α₁-acid glycoprotein (AGP), analgesia, safety, and mean plasma concentration (Cmean). Results The mean Cmax in the TAP/E+ group (0.531±0.245 µg/mL) was not significantly different from that in the TAP/E− group (0.746±0.428 µg/mL). Epinephrine significantly prolonged Tmax (165 vs 55.9 min in TAP/E−, pConclusion This study demonstrates that adding epinephrine did not alter the Cmax of ropivacaine in TAP blocks, but did prolong the time to reach Cmax. These findings support the routine inclusion of epinephrine in TAP blocks and provide a basis for multimodal analgesia strategies. Trial registration number NCT04959123.


  • Open Access

    Factors associated with poor pain experience after surgery

    by Axel Maurice-Szamburski, Romain Rozier, Victor Gridel, Vladimir Radev, Emmanuelle Badia, Anderson Loundou, Pascal Auquier, Xavier Capdevila

    Objective To identify factors associated with poor postoperative pain experience by examining patient-related and procedural variables. Methods An exploratory secondary analysis was conducted on data from 971 adult patients undergoing elective surgery under general anesthesia across five French teaching hospitals. Preoperative anxiety was assessed using the Amsterdam Preoperative Anxiety and Information Scale (APAIS). Pain, sleep quality and well-being were measured preoperatively and postoperatively using visual analog scales (VAS). The primary endpoint was the patient experience measured by the Evaluation du Vécu de l'Anesthésie Generale (EVAN-G) questionnaire on postoperative day 1, with poor pain experience defined as a score below the 25th percentile on the EVAN-G pain dimension. Univariate and multivariate logistic regression analyses were performed to identify factors associated with poor pain experience. Results Poor pain experience was reported by 271 patients (27.9%). Multivariate analysis identified intraoperative use of remifentanil and sufentanil as an independent predictor of poor pain experience with an OR of 26.96 (95% CI 2.17 to 334.23, p=0.01). Additionally, age (OR 0.97, p=0.003), absence of premedication (OR 0.49, p=0.035) and orthopedic surgery (OR 0.29, p=0.005) were associated with a lower likelihood of poor pain experience. Conversely, American Society of Anesthesiologists (ASA) 3 status (OR 5.09, p=0.028), postoperative anxiolytic use (OR 8.20, pConclusion The intraoperative use of remifentanil and sufentanil is independently associated with poorer postoperative pain experience. These findings highlight the need to reassess intraoperative analgesic strategies to enhance patient outcomes and reduce postoperative complications.


  • Anterior quadratus lumborum block in total hip arthroplasty: a two-center, randomized, placebo-controlled trial showing no additional benefit over multimodal analgesia

    by Romain Rozier, Anouk Loiseleur, Charlotte Ciais, Ophélie Moulin, Baptiste Alais, Kewan Marguerite, Emmanuelle Badia, Laurie Tran, Juliette Balbo, Axel Maurice-Szamburski

    Background Total hip arthroplasty (THA) frequently causes postoperative pain, hindering recovery and prolonging hospital stays. While multimodal analgesia aims to minimize opioid use and enhance outcomes, the optimal regional anesthesia technique is unclear due to the hip’s complex innervation. Objective This multicenter randomized placebo-controlled trial evaluated whether adding an anterior quadratus lumborum block (QLB) to multimodal analgesia with non-steroidal anti-inflammatory drugs (NSAIDs) reduces opioid consumption in THA patients. Methods 60 adults undergoing primary unilateral THA were randomized to receive either anterior QLB with 20 mL of 0.2% ropivacaine (n = 30) or a placebo saline injection (n = 30). All participants received multimodal analgesia including NSAIDs. The primary outcome was cumulative opioid consumption in oral morphine equivalents (OMEs) within the first 24 postoperative hours. Secondary outcomes included patient experience assessed by the EVAN scale on postoperative day 1, elevated pain and opioid consumption on days 1 and 2, time to first standing, walking distance and quadriceps strength on day 1, as well as walking progression, return to sport activity and analgesic use at 3 months. Results No significant difference was found in 24-hour cumulative OME consumption between groups (median 40 mg (IQR 20–50 mg) vs 31 mg (IQR 20–45 mg); p = 0.6). Patient experience, pain scores and opioid consumption were similar. Rehabilitation outcomes at 3 months also did not differ. Conclusion Adding anterior QLB to multimodal analgesia did not reduce opioid consumption or enhance postoperative pain control and functional recovery in THA patients. Anterior QLB may not provide additional benefits when combined with multimodal analgesia with NSAID for THA. Trial registration number NCT04555291.


  • Open Access

    Intravenously Administered Nonsteroidal Anti-Inflammatory Drugs in Clinical Practice: A Narrative Review

    by Axel Maurice-Szamburski, Cyril Quemeneur, Romain Rozier, Philippe Cuvillon, Claude Ecoffey

    Intravenously administered nonsteroidal anti-inflammatory drugs (NSAIDs) constitute a crucial component of multimodal analgesia strategies in surgical settings. This narrative review aims to provide an up-to-date evaluation of the efficacy, safety, and clinical use of intravenous (IV) NSAIDs for perioperative pain management in adults and children. The NSAIDs and selective COX-2 inhibitors (coxibs) approved in Europe for the short-term symptomatic treatment of acute, moderate perioperative pain via IV infusion in adults and/or children have been influenced by US and global guidelines and practice: the drugs primarily reviewed here are ibuprofen, ketorolac, ketoprofen, naproxen, paracetamol, and acetylsalicylic acid. Furthermore, intravenous ibuprofen is authorized for the short-term symptomatic treatment of fever. In contrast to intravenous ketoprofen, intravenous ibuprofen is authorized for administration to children over 6 years of age or weighing more than 20 kg. Overall, IV ibuprofen had a more favorable profile with regard to peri- and postoperative opioid sparing and pain relief. Oral ibuprofen and IV ibuprofen have similar levels of efficacy, although IV ibuprofen has a shorter onset of action and is required in patients who are unable to take oral medications. The frequency of significant adverse events appears to be similar for ibuprofen and paracetamol. Systematic reviews and meta-analyses report that intravenous NSAIDs reduce postoperative opioid consumption by approximately 20–60%, improving pain management with fewer opioid-related side effects. In indications in infants, the choice of medication is limited, and the oral route is not always feasible; IV formulations of ibuprofen are preferred in this setting. Topics for further research should include head-to-head trials of IV NSAIDs.